-Network: (11 - Statement - Statement Of Income Alternative)

-Income Statement [Abstract] {ID1}

-Statement [Table] {ID2}

-Statement [Line Items] {ID3}

-EARNINGS {ID4}

Net Sales {ID5}

Cost of products sold {ID6}

Marketing, selling and administrative {ID7}

Advertising and product promotion {ID8}

Research and development {ID9}

Acquired in-process research and development {ID10}

Provision for restructuring, net {ID11}

Litigation expense, net {ID12}

Equity in net income of affiliates {ID13}

Other (income)/expense, net {ID14}

Total Expenses, net {ID15}

Earnings from Continuing Operations Before Income Taxes {ID16}

Provision for income taxes {ID17}

Net Earnings from Continuing Operations {ID18}

-Discontinued Operations: {ID19}

Earnings, net of taxes {ID20}

Loss on Disposal, net of taxes {ID21}

Net Earnings from Discontinued Operations {ID22}

Net Earnings {ID23}

Net Earnings Attributable to Noncontrolling Interest {ID24}

Net Earnings Attributable to Bristol-Myers Squibb Company {ID25}

-Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company: {ID26}

Basic {ID27}

Diluted {ID28}

-Earnings per Common Share Attributable to Bristol-Myers Squibb Company: {ID29}

Basic {ID30}

Diluted {ID31}

Dividends declared per common share {ID32}

-Network: (12 - Statement - Statement Of Other Comprehensive Income)

-Statement of Income and Comprehensive Income [Abstract] {ID33}

-Statement [Table] {ID34}

-Statement [Line Items] {ID35}

-COMPREHENSIVE INCOME {ID36}

Net earnings {ID37}

-Other Comprehensive Income/(Loss): {ID38}

Foreign currency translation {ID39}

Foreign currency translation on hedge of a net investment {ID40}

Derivatives qualifying as cash flow hedges, net of taxes of $15 and $16 for the three months ended June 30, 2009 and 2008, respectively; and $2 and $19 for the six months ended June 30, 2009 and 2008, respectively {ID41}

Derivatives qualifying as cash flow hedges reclassified to net earnings, net of taxes of $7 and $11 for the three months ended June 30, 2009 and 2008, respectively; and $14 and $16 for the six months ended June 30, 2009 and 2008, respectively {ID42}

Pension and postretirement benefits, net of taxes of $160 and $9 for the three months ended June 30, 2009 and 2008, respectively; and $220 and $9 for the six months ended June 30, 2009 and 2008, respectively {ID43}

Pension and postretirement benefits reclassified to net earnings, net of taxes of $20 and $11 for the three months ended June 30, 2009 and 2008, respectively; and $37 and $17 for the six months ended June 30, 2009 and 2008, respectively {ID44}

Available for sale securities, net of taxes of $4 and $3 for the three months ended June 30, 2009 and 2008, respectively; and $5 and $1 for the six months ended June 30, 2009 and 2008, respectively {ID45}

Total Other Comprehensive Income/(Loss) {ID46}

Comprehensive Income {ID47}

Comprehensive Income Attributable to Noncontrolling Interest {ID48}

Comprehensive Income Attributable to Bristol-Myers Squibb Company {ID49}

-RETAINED EARNINGS {ID50}

Retained Earnings at January 1 {ID51}

Net Earnings Attributable to Bristol-Myers Squibb Company {ID52}

Cash dividends declared {ID53}

Retained Earnings at June 30 {ID54}

-Network: (13 - Statement - Statement Of Other Comprehensive Income (Parenthetical))

-Statement of Income and Comprehensive Income [Abstract] {ID55}

-Statement [Table] {ID56}

-Statement [Line Items] {ID57}

Derivatives qualifying as cash flow hedges, taxes {ID58}

Derivatives qualifying as cash flow hedges reclassified to net earnings, taxes {ID59}

Pension and postretirement benefits, taxes {ID60}

Pension and postretirement benefits reclassified to net earnings, taxes {ID61}

Available for sale securities, taxes {ID62}

-Network: (14 - Statement - Statement Of Financial Position Classified)

-Statement of Financial Position [Abstract] {ID63}

-Statement [Table] {ID64}

-Statement [Line Items] {ID65}

-ASSETS {ID66}

-Current Assets: {ID67}

Cash and cash equivalents {ID68}

Marketable securities {ID69}

Receivables, net of allowances of $130 in 2009 and $128 in 2008 {ID70}

Inventories, net {ID71}

Deferred income taxes, net of valuation allowances {ID72}

Prepaid expenses {ID73}

Total Current Assets {ID74}

Property, plant and equipment, net {ID75}

Goodwill {ID76}

Other intangible assets, net of accumulated amortization of $1,912 in 2009 and $1,802 in 2008 {ID77}

Deferred income taxes, net of valuation allowances {ID78}

Marketable securities {ID79}

Other assets {ID80}

Total Assets {ID81}

-LIABILITIES {ID82}

-Current Liabilities: {ID83}

Short-term borrowings {ID84}

Accounts payable {ID85}

Accrued expenses {ID86}

Deferred income {ID87}

Accrued rebates and returns {ID88}

U.S. and foreign income taxes payable {ID89}

Dividends payable {ID90}

Accrued litigation liabilities {ID91}

Total Current Liabilities {ID92}

Pension, postretirement and postemployment liabilities {ID93}

Deferred income {ID94}

U.S. and foreign income taxes payable {ID95}

Other liabilities {ID96}

Long-term debt {ID97}

Total Liabilities {ID98}

Commitments and contingencies (Note 21) {ID99}

-EQUITY {ID100}

-Bristol-Myers Squibb Company Shareholders' Equity: {ID101}

Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,664 in 2009 and 5,668 in 2008, liquidation value of $50 per share {ID102}

Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2009 and 2008 {ID103}

Capital in excess of par value of stock {ID104}

Restricted stock {ID105}

Accumulated other comprehensive loss {ID106}

Retained earnings {ID107}

Less cost of treasury stock -224 million common shares in 2009 and 226 million in 2008 {ID108}

Total Bristol-Myers Squibb Company Shareholders' Equity {ID109}

Noncontrolling interest {ID110}

Total Equity {ID111}

Total Liabilities and Equity {ID112}

-Network: (15 - Statement - Statement Of Financial Position Classified (Parenthetical))

-Statement of Financial Position [Abstract] {ID113}

-Statement [Table] {ID114}

-Statement [Line Items] {ID115}

Receivables, allowances {ID116}

Other intangible assets, accumulated amortization {ID117}

Preferred stock, $2 convertible series, par value {ID118}

Preferred stock, $2 convertible series, Authorized {ID119}

Preferred stock, $2 convertible series, issued {ID120}

Preferred stock, $2 convertible series, outstanding {ID121}

Preferred stock, $2 convertible series, liquidation value {ID122}

Common stock, par value {ID123}

Common stock, Authorized {ID124}

Common stock, issued {ID125}

Treasury stock, common shares {ID126}

-Network: (16 - Statement - Statement Of Cash Flows Indirect)

-Statement of Cash Flows [Abstract] {ID127}

-Statement [Table] {ID128}

-Statement [Line Items] {ID129}

-Cash Flows From Operating Activities: {ID130}

Net earnings {ID131}

-Adjustments to reconcile net earnings to net cash provided by operating activities: {ID132}

Net earnings attributable to noncontrolling interest {ID133}

Depreciation {ID134}

Amortization {ID135}

Deferred income tax expense {ID136}

Stock-based compensation expense {ID137}

Impairment charges {ID138}

Gain on sale of product lines and businesses {ID139}

Gain on debt buyback and interest swap terminations {ID140}

Gain on sale of property, plant and equipment and investment in other companies {ID141}

Acquired in-process research and development {ID142}

-Changes in operating assets and liabilities: {ID143}

Receivables {ID144}

Inventories {ID145}

Deferred income {ID146}

Accounts payable {ID147}

U.S. and foreign income taxes payable {ID148}

Changes in other operating assets and liabilities {ID149}

Net Cash Provided by Operating Activities {ID150}

-Cash Flows From Investing Activities: {ID151}

Proceeds from sale of marketable securities {ID152}

Purchases of marketable securities {ID153}

Additions to property, plant and equipment and capitalized software {ID154}

Proceeds from sale of property, plant and equipment and investment in other companies {ID155}

Proceeds from sale of product lines and businesses {ID156}

Purchase of Kosan Biosciences, Inc., net {ID157}

Proceeds from sale and leaseback of properties {ID158}

Net Cash (Used in)/Provided by Investing Activities {ID159}

-Cash Flows From Financing Activities: {ID160}

Short-term debt repayments {ID161}

Long-term debt borrowings {ID162}

Long-term debt repayments {ID163}

Interest rate swap termination {ID164}

Issuances of common stock under stock plans and excess tax benefits from share-based payment arrangements {ID165}

Dividends paid {ID166}

Proceeds from Mead Johnson initial public offering {ID167}

Net Cash (Used in)/Provided by Financing Activities {ID168}

Effect of Exchange Rates on Cash and Cash Equivalents {ID169}

(Decrease)/Increase in Cash and Cash Equivalents {ID170}

Cash and Cash Equivalents at Beginning of Period {ID171}

Cash and Cash Equivalents at End of Period {ID172}

-Network: (17 - Disclosure - Notes to Financial Statements)

-Notes to Financial Statements [Abstract] {ID173}

Note 1. Basis of Presentation and New Accounting Standards {ID174}

Note 2. Alliances and Collaborations {ID175}

Note 3. Business Segments {ID176}

Note 4. Restructuring {ID177}

Note 5. Mead Johnson Nutrition Company Initial Public Offering {ID178}

Note 6. Discontinued Operations {ID179}

Note 7. Earnings Per Share {ID180}

Note 8. Other (Income)/Expense, Net {ID181}

Note 9. Income Taxes {ID182}

Note 10. Fair Value Measurement {ID183}

Note 11. Cash, Cash Equivalents and Marketable Securities {ID184}

Note 12. Receivables, Net {ID185}

Note 13. Inventories, Net {ID186}

Note 14. Property, Plant and Equipment, Net {ID187}

Note 15. Accrued Expenses {ID188}

Note 16. Equity {ID189}

Note 17. Pension, Postretirement and Postemployment Liabilities {ID190}

Note 18. Employee Stock Benefit Plans {ID191}

Note 19. Short-Term Borrowings and Long-Term Debt {ID192}

Note 20. Financial Instruments {ID193}

Note 21. Legal Proceedings and Contingencies {ID194}

Note 22. Subsequent Event {ID195}

-Network: (18 - Document - Document Information)

-Document Information [Text Block] {ID196}

Document Type {ID197}

Amendment Flag {ID198}

Amendment Description {ID199}

Document Period End Date {ID200}

-Network: (19 - Document - Entity Information)

-Entity [Text Block] {ID201}

Trading Symbol {ID202}

Entity Registrant Name {ID203}

Entity Central Index Key {ID204}

Current Fiscal Year End Date {ID205}

Entity Well-known Seasoned Issuer {ID206}

Entity Current Reporting Status {ID207}

Entity Voluntary Filers {ID208}

Entity Filer Category {ID209}

Entity Common Stock, Shares Outstanding {ID210}

Entity Public Float {ID211}

BRISTOL MYERS SQUIBB CO XBRL Taxonomy Presentation Networks